Online citations, reference lists, and bibliographies.
← Back to Search

Efficacy And Safety Of A Novel System (NASHA/Dx Copolymer Using The Implacer Device) For Treatment Of Stress Urinary Incontinence.

P. V. van Kerrebroeck, Flip ter Meulen, G. Larsson, E. Farrelly, L. Edwall, A. Fianu-Jonasson
Published 2004 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
OBJECTIVES To investigate the efficacy and safety of non-animal-stabilized hyaluronic acid/dextranomer (NASHA/Dx) copolymer for transurethral injection using a new guiding instrument (the Implacer) for stress urinary incontinence. METHODS In an open, prospective, multicenter study, 42 invasive therapy-naive female patients with stress urinary incontinence were given 4 x 1.0 mL or 4 x 0.7 mL of NASHA/Dx copolymer using the Implacer. The efficacy parameters, measured at baseline and 1, 3, 6, and 12 months after treatment, included cough-induced leak point pressure, urine leakage by provocation test, number of incontinence episodes in 24 hours, and patient perception of bladder condition, rated on a 6-point scale. RESULTS The collected cough-induced leak point pressure data were not judged to be valid and reliable. Statistically significant reductions in median urine leakage were observed (P <0.0001), from 36 g (range 0.0-300) after 20 "jumping jacks" or vigorous coughs at baseline to 5.5 g (range 0.0-98) at 3 months and sustained at 12 months (7.0 g, range 0.0-98). Of the 42 patients, 32 (76%) demonstrated a degree of improvement in urine leakage at 3 and 12 months. The median number of incontinence episodes in 24 hours decreased significantly from 1.9 (range 0.0-24) at baseline to 0.4 (range 0.0-24) at 12 months (P <0.0001). At both 3 and 12 months, 29 patients (69%) had improved by at least one category on the 6-point patient perception scale. Treatment was well tolerated, and no complications were reported with use of the Implacer. CONCLUSIONS The results of this study indicate that a novel system (NASHA/Dx copolymer insertion using the Implacer) is an effective and well-tolerated treatment for invasive therapy-naive patients with stress urinary incontinence, with improvement sustained for at least 12 months. These encouraging results warrant additional study.
This paper references
10.1097/01.JU.0000053013.49676.89
Endoscopic treatment with dextranomer-hyaluronic acid for vesicoureteral reflux: histological findings.
A. Stenberg (2003)
10.1016/S0022-5347(01)64185-5
Lack of distant migration after injection of a 125iodine labeled dextranomer based implant into the rabbit bladder.
A. Stenberg (1997)
10.1111/j.1651-2227.1999.tb01320.x
Endoscopic treatment of children with vesico‐ureteric reflux
G. Läckgren (1999)
10.1034/j.1600-0412.1999.780517.x
DiHA Dextran Copolymer, a new biocompatible material for endoscopic treatment of stress incontinent women, Short term results
A. Stenberg (1999)
10.1007/BF00328107
The standardisation of terminology of lower urinary tract function
P. Abrams (2004)
10.1016/S0022-5347(05)65713-8
Long-term followup of children treated with dextranomer/hyaluronic acid copolymer for vesicoureteral reflux.
G. Läckgren (2001)
10.1007/s00240-002-0290-1
Treatment of stress urinary incontinence: recent developments in the role of urethral injection
P. Kerrebroeck (2003)
10.1007/BF01895097
Reproducibility of a new method to determine cough-induced leak-point pressure in women with stress urinary incontinence
H. Siltberg (2005)
10.1080/003655999750016988
Injectable dextranomer-based implant: histopathology, volume changes and DNA-analysis.
A. Stenberg (1999)
10.1097/00042307-200207000-00012
Review of the available urethral bulking agents
D. Lightner (2002)
10.1016/S0022-5347(05)66940-6
Outcome results of transurethral collagen injection for female stress incontinence: assessment by urinary incontinence score.
A. Groutz (2000)
10.1007/s00192-003-1075-y
Urethral injection for stress urinary incontinence: long-term results with dextranomer/hyaluronic acid copolymer
Å. Stenberg (2003)
Current status of injectable agents for female stress urinary incontinence.
S. Herschorn (2001)
10.3109/07853899009147286
Treatment of stress urinary incontinence.
W. Fischer‐Rasmussen (1990)
10.1034/j.1600-0412.2003.00257.x
Stress urinary incontinence: feasibility of surgery after urethral injection
A. Fianu-Jonasson (2003)
Stress Urinary Incontinence
E. Mcguire (1976)
10.1002/NAU.10052
The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence Society
P. Abrams (2002)
10.1016/S0022-5347(05)65768-0
Collagen implant for treating stress urinary incontinence in women with urethral hypermobility.
A. Bent (2001)
Collagen injection therapy for urinary incontinence.
Appell Ra (1994)



This paper is referenced by
10.1111/j.1464-410X.2004.05101.x
Treatment of stress urinary incontinence using a copolymer system: impact on quality of life
P. V. van Kerrebroeck (2004)
10.1016/j.ucl.2012.05.002
Urethral bulking: a urology perspective.
W. S. Reynolds (2012)
10.5301/RU.2010.5941
Bulking agents: anesthesia techniques.
M. A. Cerruto (2009)
10.1111/j.1464-410X.2006.06072.x
Advancing the treatment of stress urinary incontinence
P. Costa (2006)
10.1100/tsw.2009.53
Minimally Invasive Therapies for Female Stress Urinary Incontinence: the Current Status of Bioinjectables/New Devices (Adjustable Continence Therapy, Urethral Submucosal Collagen Denaturation by Radiofrequency)
S. Crivellaro (2009)
10.1097/01.mou.0000172396.54643.96
An evidence-based approach to the evaluation and management of stress incontinence in women
Jason P. Gilleran (2005)
10.1177/039156030907600107
Bulking Agents: Anesthesia Techniques
M. Cerruto (2009)
10.1586/17434440.1.2.205
Injection therapy for stress urinary incontinence in adult women.
P. T. Meulen (2004)
10.1016/J.PUROL.2008.06.002
Pseudokystes periurétraux en complication des injections urétrales de Zuidex® : revue de la littérature
C. Loisel (2008)
Yes No Systemic toxicity No Possible Cardiovascular stability Variable Good Outcome predictability Yes Variable Analgesia quality Good Variable Headache Possible No Topographic selectivity Yes Variable
M. A. Cerruto (2009)
Procedimientos cosméticos en ginecología
R. Merino (2012)
10.1007/s00192-011-1377-4
Case reports: periurethral bulking agents and presumed urethral diverticula
Disha Kumar (2011)
10.1007/978-3-319-98264-9
Complications of Surgery for Male Urinary and Fecal Incontinence
Salvatore Siracusano (2020)
Radiopaque bioactive microspheres as injectable biomaterials
K. Saralidze (2008)
10.1007/978-1-84628-510-3_12
Surgery for Stress Urinary Incontinence: Minimally Invasive Procedures
Eric A. Hurtado (2009)
10.1517/14656566.7.11.1441
Injectables for the treatment of stress urinary incontinence: current use and future perspectives
P. Perimenis (2006)
10.1016/J.EURURO.2005.05.007
An open, multicentre study of NASHA/Dx Gel (Zuidex) for the treatment of stress urinary incontinence.
C. Chapple (2005)
10.1016/j.urology.2009.05.034
Randomized controlled multisite trial of injected bulking agents for women with intrinsic sphincter deficiency: mid-urethral injection of Zuidex via the Implacer versus proximal urethral injection of Contigen cystoscopically.
D. Lightner (2009)
10.3390/ma3063537
Polymeric Microspheres for Medical Applications
K. Saralidze (2010)
10.1007/S11934-009-0062-3
Urethral bulking agents: Techniques and outcomes
A. Kotb (2009)
10.1016/J.EURURO.2005.06.012
Stress incontinence injection therapy: what is best for our patients?
C. Chapple (2005)
10.1016/j.urology.2009.01.070
Periurethral non-animal stabilized hyaluronic acid/dextranomer injections: efficacy and formation of granuloma/sterile abscess.
A. Sahai (2009)
10.4995/THESIS/10251/48799
Structures based on semi-degradable biomaterials for neural regeneration in the central nervous system
M. P. Garnes (2015)
10.1016/B978-1-4160-2339-5.50080-X
Chapter 31 – URETHRAL INJECTABLES IN THE MANAGEMENT OF STRESS URINARY INCONTINENCE
E. Elzayat (2008)
10.1167/iovs.08-2801
Outflow facility in isolated porcine eyes after creation of an intrascleral canal by injection of stabilized hyaluronic acid.
N. Mavrakanas (2009)
10.1007/s00192-006-0148-0
Patient-perceived outcomes in the treatment of stress urinary incontinence: focus on urethral injection therapy
C. Chapple (2006)
10.1159/000209832
NASHA/Dx Gel (ZuidexTM) for Stress Urinary Incontinence: Results from a Single-Centre Study of 150 Patients
C. Blick (2008)
10.4081/aiua.2014.3.205
Injection devices for bulking agents in uro-gynaecology.
M. A. Cerruto (2014)
10.1111/j.1742-1241.2006.01056.x
Magnetic resonance imaging to evaluate NASHA/Dx gel (ZuidexTM) for stress urinary incontinence
A. Fianu-Jonasson (2006)
10.1007/S11934-006-0012-2
Emerging periurethral bulking agents for female stress urinary incontinence: is new necessarily better?
J. Starkman (2006)
10.5336/MEDSCI.2010-18067
Effectiveness of Periurethral Injection on Stress Urinary Incontinence
A. Güngören (2011)
10.1089/END.2006.20.1082
Macroplastique implantation system for female stress urinary incontinence: long-term follow-up.
J. T. Tamanini (2006)
See more
Semantic Scholar Logo Some data provided by SemanticScholar